SuperworthAgenus EPS AGEN
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $2.64
- Latest quarter, Q2 FY26
- −$0.01
- Fiscal year 2025
- −$0.40
Agenus' earnings per share was $2.64 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.01.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.40 | n/a |
| FY2024 | −$10.65 | n/a |
| FY2023 | −$13.95 | n/a |
| FY2022 | −$15.60 | n/a |
| FY2021 | −$3.60 | n/a |
| FY2020 | −$21.40 | n/a |
| FY2019 | −$16.20 | n/a |
| FY2018 | −$29.20 | n/a |
| FY2017 | −$24.40 | n/a |
| FY2016 | −$29.40 | n/a |
| FY2015 | −$23.00 | n/a |
| FY2014 | n/a | n/a |
| FY2013 | −$23.00 | n/a |
| FY2012 | −$9.80 | n/a |
| FY2011 | −$24.20 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.01 | n/a | $2.64 | |
| Q1 FY26 | $1.02 | n/a | $1.65 | |
| Q4 FY25 | −$0.31 | n/a | −$0.40 | |
| Q3 FY25 | $1.94 | n/a | −$2.10 | |
| Q2 FY25 | −$1.00 | n/a | −$7.12 | |
| Q1 FY25 | −$1.03 | n/a | −$8.64 | |
| Q4 FY24 | −$2.01 | n/a | −$10.65 | |
| Q3 FY24 | −$3.08 | n/a | −$11.06 | |
| Q2 FY24 | −$2.52 | n/a | −$11.27 | |
| Q1 FY24 | −$3.04 | n/a | −$12.68 | |
| Q4 FY23 | −$2.42 | n/a | −$13.95 | |
| Q3 FY23 | −$3.29 | n/a | −$16.13 |
Against its peers
Companies in Biotechnology nearest Agenus' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AGENAgenus | $2.64 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Agenus
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.